HRP20220999T1 - Terapija za ulcerozni kolitis zasnovana na oligonukleotidu - Google Patents
Terapija za ulcerozni kolitis zasnovana na oligonukleotidu Download PDFInfo
- Publication number
- HRP20220999T1 HRP20220999T1 HRP20220999TT HRP20220999T HRP20220999T1 HR P20220999 T1 HRP20220999 T1 HR P20220999T1 HR P20220999T T HRP20220999T T HR P20220999TT HR P20220999 T HRP20220999 T HR P20220999T HR P20220999 T1 HRP20220999 T1 HR P20220999T1
- Authority
- HR
- Croatia
- Prior art keywords
- oligonucleotide
- subject
- use according
- single doses
- administered
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims 28
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 title claims 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- IXYNFLOLUBKHQU-FZCWJHTDSA-N [(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl] hydrogen phosphate Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O IXYNFLOLUBKHQU-FZCWJHTDSA-N 0.000 claims 3
- 229950001404 cobitolimod Drugs 0.000 claims 3
- 241000792859 Enema Species 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000007920 enema Substances 0.000 claims 2
- 229940095399 enema Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000011861 anti-inflammatory therapy Methods 0.000 claims 1
- 238000012321 colectomy Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Oligonukleotid koji se sastoji iz sekvence
5’-GGAACAGTTCGTCCATGGC-3’ (SEQ ID NO:2) za upotrebu u liječenju upalne bolesti crijeva u humanom subjektu preko lokalne primjene u debelom crijevu, pri čemu subjekt nije bio izložen čišćenju debelog crijeva prije spomenute primjene.
2. Oligonukleotid za upotrebu prema zahtjevu 1, pri čemu se spomenuta lokalna primjena vrši preko klizme koja je pogodna za samostalnu primjenu od strane pacijenta, poželjno gdje spomenuta klizma ima izduženi vrh oblikovan tako da omogući umetanje u rektum, poželjnije gdje spomenuti izduženi vrh ima dužinu od 4 do 10 cm.
3. Oligonukleotid za upotrebu prema zahtjevu 1 ili zahtjevu 2, pri čemu subjekt nije bio izložen čišćenju debelog crijeva tokom 24 h prije tretmana s oligonukleotidom, poželjno tokom 48 h prije tretmana s oligonukleotidom.
4. Oligonukleotid za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu spomenuta upalna bolest crijeva je ulcerozni kolitis, poželjno gdje je subjektu dijagnosticiran ulcerozni kolitis lijeve strane.
5. Oligonukleotid za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu su pojedinačne doze od 150mg do 350mg spomenutog oligonukleotida primijenjene na subjektu u bar dva odvojena slučaja, pri čemu su spomenuti slučajevi u razmaku od 3 tjedna.
6. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je subjekt otporan ili nedovoljno reagira ili je intolerantan na terapiju protiv upale.
7. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je spomenuti subjekt odabran za kolektomiju.
8. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu spomenuti oligonukleotid ima sekvencu 5’-GGAACAGTTCGTCCATGGC-3’ (SEQ ID NO:2), u kojoj je CG dinukleotid nemetiliran.
9. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu spomenuti oligonukleotid ima sekvencu 5’- G∗G∗A∗ACAGTTCGTCCAT∗G∗G∗C-3’ (SEQ ID NO:1), u kojoj je CG dinukleotid nemetiliran, i ∗ označava fosforotioatnu internukleozidnu vezu, poželjno pri čemu je oligonukleotid kobitolimod.
10. Oligonukleotid za upotrebu prema bilo kojem od zahtjeva 5 do 9, gdje su primijenjene pojedinačne doze od 240mg do 260mg spomenutog oligonukleotida.
11. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje su primijenjene pojedinačne doze od oko 250mg spomenutog oligonukleotida.
12. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje
(a) pojedinačne doze spomenutog oligonukleotida su primijenjene na subjektu u samo dva odvojena slučaja u razmaku od 3 tjedna; ili
(b) pojedinačne doze spomenutog oligonukleotida su primijenjene na subjektu u dva ili više odvojenih slučajeva u razmaku od 3 tjedna do postizanja remisije kod subjekta.
13. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje subjekt dobiva jedan ili više dodatnih terapeutskih sredstava za liječenje upalne bolesti crijeva, obično ulceroznog kolitisa.
14. Oligonukleotid za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje je oligonukleotid kobitolimod, i pojedinačne doze od oko 250mg kobitolimoda su primijenjene na subjektu u samo dva odvojena slučaja u razmaku od 3 tjedna.
15. Farmaceutski sastav koji sadrži oligonukleotid kao što je definirano u bilo kojem od zahtjeva 1, 8 i 9, zajedno s jednim ili više farmaceutski prihvatljivih nosača, za upotrebu u liječenju upalne bolesti crijeva kao što je definirano u bilo kojem od zahtjeva 1 i 4 u humanom subjektu kao što je definirano u bilo kojem od zahtjeva 1, 3, 6, 7 i 13, poželjno gdje su pojedinačne primjene spomenutog sastava primijenjene na subjektu u bar dva odvojena slučaja, pri čemu su spomenuti odvojeni slučajevi u razmaku od 3 tjedna, i poželjno gdje svaka primjena sastava isporučuje količinu oligonukleotida kao što je definirano u bilo kojem od zahtjeva 5, 10, 11 i 14.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1912191.2A GB201912191D0 (en) | 2019-08-24 | 2019-08-24 | New therapy |
| EP20760858.9A EP3947685B1 (en) | 2019-08-24 | 2020-08-21 | Oligonucleotide-based therapy for ulcerative colitis |
| PCT/EP2020/073566 WO2021037764A1 (en) | 2019-08-24 | 2020-08-21 | Oligonucleotide-based therapy for ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220999T1 true HRP20220999T1 (hr) | 2022-11-11 |
Family
ID=68108901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220999TT HRP20220999T1 (hr) | 2019-08-24 | 2020-08-21 | Terapija za ulcerozni kolitis zasnovana na oligonukleotidu |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220378818A1 (hr) |
| EP (1) | EP3947685B1 (hr) |
| JP (1) | JP2022545692A (hr) |
| KR (2) | KR102592716B1 (hr) |
| CN (1) | CN114599376A (hr) |
| AU (1) | AU2020335171A1 (hr) |
| BR (1) | BR112022002612A2 (hr) |
| CA (1) | CA3151203A1 (hr) |
| DK (1) | DK3947685T3 (hr) |
| ES (1) | ES2925460T3 (hr) |
| GB (1) | GB201912191D0 (hr) |
| HR (1) | HRP20220999T1 (hr) |
| HU (1) | HUE059642T2 (hr) |
| LT (1) | LT3947685T (hr) |
| PL (1) | PL3947685T3 (hr) |
| PT (1) | PT3947685T (hr) |
| RS (1) | RS63640B1 (hr) |
| SI (1) | SI3947685T1 (hr) |
| WO (1) | WO2021037764A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202018468D0 (en) * | 2020-11-24 | 2021-01-06 | Index Pharmaceuticals Ab | New therapy |
| EP4147688A1 (en) | 2021-09-09 | 2023-03-15 | InDex Pharmaceuticals AB | Enema formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| EP2596806A1 (en) * | 2011-11-25 | 2013-05-29 | Index Pharmaceuticals AB | Method for prevention of colectomy |
| GB201707503D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New Therapy 3 |
| GB201707501D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New therapy 2 |
-
2019
- 2019-08-24 GB GBGB1912191.2A patent/GB201912191D0/en not_active Ceased
-
2020
- 2020-08-21 PL PL20760858.9T patent/PL3947685T3/pl unknown
- 2020-08-21 DK DK20760858.9T patent/DK3947685T3/da active
- 2020-08-21 CA CA3151203A patent/CA3151203A1/en active Pending
- 2020-08-21 HU HUE20760858A patent/HUE059642T2/hu unknown
- 2020-08-21 KR KR1020227008943A patent/KR102592716B1/ko active IP Right Grant
- 2020-08-21 SI SI202030081T patent/SI3947685T1/sl unknown
- 2020-08-21 US US17/636,317 patent/US20220378818A1/en active Pending
- 2020-08-21 KR KR1020237035700A patent/KR20230148402A/ko not_active Application Discontinuation
- 2020-08-21 JP JP2022512470A patent/JP2022545692A/ja not_active Withdrawn
- 2020-08-21 ES ES20760858T patent/ES2925460T3/es active Active
- 2020-08-21 CN CN202080074381.1A patent/CN114599376A/zh active Pending
- 2020-08-21 RS RS20220939A patent/RS63640B1/sr unknown
- 2020-08-21 PT PT207608589T patent/PT3947685T/pt unknown
- 2020-08-21 WO PCT/EP2020/073566 patent/WO2021037764A1/en unknown
- 2020-08-21 EP EP20760858.9A patent/EP3947685B1/en active Active
- 2020-08-21 HR HRP20220999TT patent/HRP20220999T1/hr unknown
- 2020-08-21 LT LTEPPCT/EP2020/073566T patent/LT3947685T/lt unknown
- 2020-08-21 BR BR112022002612A patent/BR112022002612A2/pt unknown
- 2020-08-21 AU AU2020335171A patent/AU2020335171A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021037764A1 (en) | 2021-03-04 |
| ES2925460T3 (es) | 2022-10-18 |
| KR20230148402A (ko) | 2023-10-24 |
| CA3151203A1 (en) | 2021-03-04 |
| SI3947685T1 (sl) | 2022-09-30 |
| PL3947685T3 (pl) | 2022-11-21 |
| EP3947685A1 (en) | 2022-02-09 |
| EP3947685B1 (en) | 2022-07-13 |
| HUE059642T2 (hu) | 2022-12-28 |
| KR20220050927A (ko) | 2022-04-25 |
| AU2020335171A1 (en) | 2022-02-24 |
| US20220378818A1 (en) | 2022-12-01 |
| BR112022002612A2 (pt) | 2022-05-03 |
| DK3947685T3 (da) | 2022-08-08 |
| GB201912191D0 (en) | 2019-10-09 |
| CN114599376A (zh) | 2022-06-07 |
| KR102592716B1 (ko) | 2023-10-20 |
| RS63640B1 (sr) | 2022-10-31 |
| PT3947685T (pt) | 2022-08-18 |
| JP2022545692A (ja) | 2022-10-28 |
| LT3947685T (lt) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | GSK-3β inhibitors suppressed neuroinflammation in rat cortex by activating autophagy in ischemic brain injury | |
| HRP20220999T1 (hr) | Terapija za ulcerozni kolitis zasnovana na oligonukleotidu | |
| HRP20191723T1 (hr) | Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa | |
| JP2018529732A5 (hr) | ||
| JP2010511039A5 (hr) | ||
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JP2019527714A5 (hr) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| AU2018265211B2 (en) | Cobitolimod for use in the treatment of inflammatory bowel disease | |
| JP2016523548A5 (hr) | ||
| KR20160040697A (ko) | 염증성 장 질환 치료를 위한 약제의 제조에서 안드로그라폴라이드의 적용, 안드로그라폴라이드 장용성 표적화 마이크로펠릿 및 그의 제조방법 | |
| US11795462B2 (en) | Therapy | |
| Piglionica et al. | The gut–liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19 | |
| JP2017512194A5 (hr) | ||
| JP2011500650A5 (hr) | ||
| JP2019524160A5 (hr) | ||
| CN101988057B (zh) | 启动子及其应用 | |
| CA3202097A1 (en) | Cobitolimod dosage for self-administration | |
| Pandiri et al. | Medicinal applications of antisense oligonucleotides: a review | |
| SRESHTAA | Rivelin Patch-Treatment for Oral Ulcers. | |
| Naryshkin et al. | P3. 12 Small molecule compounds that correct alternative splicing of the SMN2 gene and restore SMN protein expression and function | |
| Yoo et al. | Musk of the Ondatra zibethicus Protect Ischemic Injury in the Gerbil Hippocampus | |
| Olsen et al. | 881. Pseudotype Switching as a Strategy To Permit Efficient Re-Administration of Lentiviral Vectors to Mouse Airways | |
| Kerman et al. | Management of Distal Colitis | |
| CN104055914A (zh) | 一种用于治疗肛裂的中药 |